Evidence map›Paper›PMID 34965902›Full record

ArticleJournal of hepatology2022

Corrigendum to 'TAZ is indispensable for c-MYC-induced hepatocarcinogenesis' [J Hepatol (2022) 123-134].

Haichuan Wang, Shanshan Zhang, Yi Zhang, Jiaoyuan Jia, Jingxiao Wang, Xianqiong Liu, Jie Zhang, Xinhua Song, Silvia Ribback, Antonio Cigliano and 6 more

Open access · greenAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Mechanism of action and treatment of type I interferon in hepatocellular carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 3 countries.

Haichuan WangLiver Transplantation Division, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA.
Shanshan ZhangDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA.
Yi ZhangDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA.
Jiaoyuan JiaDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA; Department of Oncology and Hematology, the Second Hospital, Jilin University, Changchun, China.
Jingxiao WangDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA; School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
Xianqiong LiuDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA; School of Pharmacy, Hubei University of Chinese Medicine Wuhan, Hubei, China.
Jie ZhangDepartment of Thoracic Oncology II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, People's Republic of China.
Xinhua SongDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA.
Silvia RibbackInstitute of Pathology, University of Greifswald, Greifswald, Germany.
Antonio CiglianoInstitute of Pathology, University of Regensburg, Regensburg, Germany.
Matthias EvertInstitute of Pathology, University of Regensburg, Regensburg, Germany.
Bingyong LiangDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA; Hepatic Surgery Center, Department of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hong WuLiver Transplantation Division, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Diego F CalvisiInstitute of Pathology, University of Regensburg, Regensburg, Germany. Electronic address: diego.calvisi@klinik.uni-regensburg.de.
Yong ZengLiver Transplantation Division, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: zengyong@medmail.com.cn.
Xin ChenDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA. Electronic address: xin.chen@ucsf.edu.
University of California, San Francisco · USUniversity of Regensburg · DESichuan University · CNBeijing University of Chinese Medicine · CNHuazhong University of Science and Technology · CNPeking University · CNUniversität Greifswald · DE

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
NIDDK NIH HHS P30 DK026743
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34965902
PMCPMC10508224
OpenAlexW4200102531

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.